Andre Turenne, Matchpoint Therapeutics CEO (Jen Randall Photography)
October 14, 2022 06:30 AM EDTUpdated October 25, 01:44 PM
Financing
Startups

For­mer Voy­ager CEO An­dre Turenne makes a come­back with At­las-backed co­va­lent drug biotech 

Lei Lei Wu

News Reporter

Last May, An­dre Turenne re­signed from his CEO and pres­i­dent posts at Voy­ager to “pur­sue oth­er op­por­tu­ni­ties” af­ter the neu­ro­science biotech, once one half …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times